Retinitis Pigmentosa Clinical Trials in Philadelphia, PA

View the best 10 retinitis pigmentosa medical studies in Philadelphia, Pennsylvania. Access promising new therapies by applying to a Philadelphia-based Retinitis Pigmentosa clinical trial.

Trials in Philadelphia, Pennsylvania

Here are the top 7 medical studies for retinitis pigmentosa in Philadelphia, Pennsylvania

AGTC-501

Virus Therapy

Recruiting1 awardPhase 2 & 3

This trial will test two different doses of a gene therapy called AGTC-501 to see how safe and effective it is in treating a certain type of eye disease in men.

OCU400

Gene Therapy

Recruiting1 awardPhase 1 & 2

This trial tests OCU400, an eye injection, in patients with specific genetic mutations causing RP and LCA. The treatment aims to correct faulty genes to prevent vision loss.

N-acetylcysteine

Antioxidant

Recruiting1 awardPhase 3

This trial is testing if N-acetylcysteine (NAC) can help slow down vision loss in people with Retinitis Pigmentosa (RP). RP is a genetic condition that causes gradual vision loss. NAC reduces damage caused by too much oxygen around eye cells, potentially protecting vision. N-acetylcysteine (NAC) has been shown to reduce oxidative damage and increase cone function/survival in studies related to RP.

BIIB111 +1 More

Gene Therapy

Recruiting2 awardsPhase 3

This trial will compare the long-term safety and efficacy of a sub-retinal injection of BIIB111 in participants with Choroideremia (CHM) who have been previously treated with BIIB111, with untreated control participants who have exited the STAR (NCT03496012) study. The trial will also compare BIIB112 in participants with X-linked retinitis pigmentosa (XLRP) who have been previously treated with BIIB112.

4D-125 IVT Injection

Recruiting1 awardPhase 1 & 2

This trial tests a new eye injection treatment for males with a genetic eye disease. The treatment replaces a faulty gene with a healthy one to help stop or slow down the disease. Gene therapy has been extensively studied and shows promise for treating genetic eye diseases by delivering functional genes to replace faulty ones.

NAC effervescent tablets

Antioxidant

Recruiting2 awardsPhase 1

This trial is testing N-acetylcysteine (NAC) tablets to help people with Retinitis Pigmentosa (RP), a disease that causes vision loss. NAC is an antioxidant that protects eye cells from damage. The goal is to see if NAC can slow down or stop the progression of vision loss in RP patients.

BS01

Virus Therapy

Recruiting1 awardPhase 1 & 2

This trial tests a modified virus that carries a light-sensitive gene to help people with vision problems. The virus delivers this gene to eye cells, making them respond to light and potentially improving vision.

Popular Filters

Trials With No Placebo

Gene Therapy

OCU400 for Retinitis Pigmentosa

Recruiting1 awardPhase 1 & 2

Philadelphia, Pennsylvania

This trial tests OCU400, an eye injection, in patients with specific genetic mutations causing RP and LCA. The treatment aims to correct faulty genes to prevent vision loss.

Virus Therapy

AGTC-501 for Retinitis Pigmentosa

Recruiting1 awardPhase 2 & 3

Philadelphia, Pennsylvania

This trial will test two different doses of a gene therapy called AGTC-501 to see how safe and effective it is in treating a certain type of eye disease in men.

4D-125 for Retinitis Pigmentosa

Recruiting1 awardPhase 1 & 2

New York, New York

This trial tests a new eye injection treatment for males with a genetic eye disease. The treatment replaces a faulty gene with a healthy one to help stop or slow down the disease. Gene therapy has been extensively studied and shows promise for treating genetic eye diseases by delivering functional genes to replace faulty ones.

Virus Therapy

Gene Therapy for Retinitis Pigmentosa

Recruiting1 awardPhase 1 & 2

New York, New York

This trial tests a modified virus that carries a light-sensitive gene to help people with vision problems. The virus delivers this gene to eye cells, making them respond to light and potentially improving vision.

Antioxidant

N-acetylcysteine for Retinitis Pigmentosa

Recruiting2 awardsPhase 1

Baltimore, Maryland

This trial is testing N-acetylcysteine (NAC) tablets to help people with Retinitis Pigmentosa (RP), a disease that causes vision loss. NAC is an antioxidant that protects eye cells from damage. The goal is to see if NAC can slow down or stop the progression of vision loss in RP patients.

Gene Therapy

Gene Therapy for Leber Congenital Amaurosis

Recruiting1 awardPhase 1 & 2

Philadelphia, Pennsylvania

This trial is testing a new gene therapy for people with a specific genetic mutation that causes Leber Congenital Amaurosis, a severe form of vision loss.

Frequently Asked Questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

Is there any support for travel costs?

Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.

Will I know what medication I am taking?

This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.

How long do clinical trials last?

Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.

Do you verify all the trials on your website?

All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.

How quickly will I hear back from a clinical trial?

Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.